/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

MONTE ROSA THERAPEUTICS INC share price today is $15.97, up -5.98%. The stock opened at $16.87 against the previous close of $17.06, with an intraday high of $16.87 and low of $15.73.

style

pb-0

MONTE ROSA THERAPEUTICS INC

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$15.97 -0.0598(-5.98%) GLUE at 13 Mar 2026 01:19 PM Biotechnology

Lowest Today 15.73

Highest Today 16.87

Today’s Open 16.87

Prev. Close 17.06

52 Week High 25.77

52 Week Low 3.50

Day’s Range: Low 15.73 High 16.87

52-Week Range: Low 3.50 High 25.77

MONTE ROSA THERAPEUTICS INC Institutional Holdings

MONTE ROSA THERAPEUTICS INC Market Status

Strong Buy: 6

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

MONTE ROSA THERAPEUTICS INC Fundamentals

Market Cap 1300.70 M

PB Ratio 5.2909

PE Ratio 53.3125

Enterprise Value 949.61 M

Total Assets 438.73 M

Volume 1171879

MONTE ROSA THERAPEUTICS INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-132882000 -132.9M, FY22:-104618000 -104.6M, FY21:-71942000 -71.9M, FY20:-36068000 -36.1M, FY19:-8017000 -8.0M

Quarterly Revenue Q3/2025:12768000 12.8M, Q2/2025:23194000 23.2M, Q1/2025:84929000 84.9M, Q3/2024:9216000 9.2M, Q2/2024:4695000 4.7M

Quarterly Profit Q3/2025:10673000 10.7M, Q2/2025:23194000 23.2M, Q1/2025:84929000 84.9M, Q3/2024:9216000 9.2M, Q2/2024:2635000 2.6M

Quarterly Net worth Q3/2025:-27081000 -27.1M, Q2/2025:-12295000 -12.3M, Q1/2025:46885000 46.9M, Q3/2024:-23859000 -23.9M, Q2/2024:-30310000 -30.3M

About MONTE ROSA THERAPEUTICS INC & investment objective

Company Information Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 147

Industry Biotechnology

CEO Dr. Markus Warmuth M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*